Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1 6Phase 3 5Phase NA 2Phase 1/2 2

Status

Completed 3Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 18Thoracic 13Gastrointestinal 13Genitourinary 9Lymphoid 5Head & Neck 5Gynecologic 5Other hematologic neoplasm 4Plasma cell 3Other solid neoplasm 3Endocrine 2Classical hematology 2Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Nasopharyngeal Carcinoma 2Thyroid Cancer, Papillary 1Recurrence 1Neoplasm Metastasis 1Adenocarcinoma, Follicular 1

Interventions

Cisplatin 144Radiotherapy 71Fluorouracil 50Radiotherapy, Intensity-Modulated 45Docetaxel 39Gemcitabine 38Cetuximab 38Carboplatin 31pembrolizumab 25Capecitabine 22Drug Therapy 17toripalimab 14Paclitaxel 14camrelizumab 10Surgical Procedures, Operative 10Nivolumab 10Chemoradiotherapy 10nimotuzumab 9Radiation 9Neoadjuvant Therapy 8Methotrexate 8Magnetic Resonance Spectroscopy 8Chemotherapy, Adjuvant 8nedaplatin 7Thyrotropin Alfa 7Platinum 7tislelizumab 6spartalizumab 6Standard of Care 6Specimen Handling 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Injections × Head & Neck × Clear all
NCT05294172 2026-05-08

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 3 Active not recruiting
295 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT05802290 2023-04-06

NIVACTOR

Gruppo Oncologico del Nord-Ovest

Phase 3 Completed
124 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT01265849 2022-08-19

IT-MATTERS

CEL-SCI Corporation

Phase 3 Completed
928 enrolled 25 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03707509 2022-07-01

Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Unknown
263 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT00295763 2015-03-18

A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.

Sanofi

Phase 3 Completed
61 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡